Creative Biolabs is a global leader in antimicrobial resistance drug development. Through our state-of-the-art facilities and extensive experience, we offer a full range of drug development services, including target identification and validation, hit identification, hit to lead, lead optimization, pharmacological characterization, drug effectiveness, and safety evaluation. As a service provider, our goal is to provide the highest level of service, confidentiality and customer support.
Shigella are facultatively anaerobic, spore-free, rod-shaped gram-negative bacteria. Based on biochemical and serological characteristics, Shigella is classified into four types: S dysenteriae (serogroup A), S flexneri (serogroup B), S. boydii (serogroup C) and S.sonnei (serogroup D). Serogroups A, B, and C are very similar physiologically while S. sonnei can be distinguished from the other serogroups by positive β-D-galactosidase and ornithine decarboxylase biochemical reactions. The identification of Shigella by species is usually accomplished by slide agglutination using commercially available, absorbed rabbit antisera.
Shigella usually causes shigellosis, also known as bacillary dysentery. Symptoms of shigellosis include abdominal pain, tenesmus, watery diarrhea, and/or dysentery (multiple scanty, bloody, mucoid stools). Other signs may include abdominal tenderness, fever, vomiting, dehydration, and convulsions.
Antibiotic treatment of common bacterial infections plays an important role in reducing the prevalence and mortality of the disease. However, incorrect antibiotic use or overuse in treating diarrhea increases antibiotic resistance. Shigella is resistant to most antibiotics. For example, most Shigella are resistant to chloramphenicol (Chl), ampicillin (Amp), tetracycline (Tet), and trimethoprim-sulfamethoxazole (Sxt), while about half of the Shigella strains are multidrug-resistant. Drug resistance of Shigella may be caused by a variety of mechanisms, such as extrusion of drugs by active efflux pumps, decrease in cellular permeability, and overexpression of drug-modifying and -inactivating enzymes or target modification by mutation.
Because Shigella is resistant to most antibiotics, and some strains are multidrug-resistant, the development of new antibiotics or drugs is necessary to treat infections caused by Shigella. Empowered by leading technology and years of experience in drug development, Creative Biolabs offers a broad range of services to support drug discovery research processes including target choosing, screening compound libraries, discovering and validating hits, developing lead compounds, characterizing the pharmacological profile, testing toxicity in animal models, determining efficacy in treating bacterial infections. Our integrated drug development services are designed to reduce your costs and timelines, helping you meet your drug discovery milestones.
If what you are looking for is not on the list, please contact us and we will gladly meet your drug discovery needs.
For Research Use Only.
